Study conducted by 13 organisations found that in govt hospitals, direct median total cost for treating bloodstream ...

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA ...

Basilea Pharma awarded USD 7.3 million additional CARB-X funding to develop new drug candidate from a novel class of antibiotics: Allschwil, Switzerland Thursday, December 26, 202 ...

Importantly, the medicine has been found to be highly effective against gram negative bacteria—the pathogens that are particularly difficult to treat and are a big challenge in the Indian context. In ...

Most diabetic wound care products are passive dressings, only providing a protective barrier against the external environment ...

MV-130 is under clinical development by Inmunotek and currently in Phase II for Lower Respiratory Tract Infections.

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc ...

The initial use of combination antimicrobial therapy for gram-negative infections is usually ... risk of superinfection with more-resistant bacteria or fungi. There are no clinical data that ...

This beta lactamase inhibitor combats against resistant gram-negative bacteria causing cUTI; VAP and HAP along with bacteria. Relebactam too is a new ß-lactamase inhibitor that increases effectiveness ...

The next time you order an iced drink at a restaurant, ask yourself this: How safe are those ice cubes really, and how clean ...

An illustration depicting a three-dimensional (3D), computer-generated image, of a group of Gram-negative, Legionella pneumophila, bacteria. A teacher at Pasadena Fundamental Elementary School ...